Danger signalling during cancer cell death: Origins, plasticity and regulation

Cell Death and Differentiation

Volumn 21, Issue 1, 2014, Pages 26-38

  Garg, A D ^a   Martin, S ^a   Golab, J ^b,c   Agostinis, P ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c INSTITUTE OF PHYSICAL CHEMISTRY   (Poland)

Author keywords

anti tumour immunity; cancer; DAMPs; danger signals; immunogenic cell death; immunogenicity; tumour immunology

Indexed keywords

BORTEZOMIB; CHAPERONE; CHEMOKINE RECEPTOR CXCR3; CYCLOPHOSPHAMIDE; DIGITOXIN; DIGOXIN; DOXORUBICIN; FLUOROURACIL; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; GEMCITABINE; IDARUBICIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; MITOXANTRONE; MYELOID DIFFERENTIATION FACTOR 88; OXALIPLATIN; PERFORIN; PROTEIN BAX; SHIKONIN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR RECEPTOR; WOGONIN;

APOPTOSIS; CANCER CELL; CELL DEATH; COXSACKIE VIRUS; DEGRADATION; ENDOPLASMIC RETICULUM STRESS; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PLASTICITY; PRIORITY JOURNAL; REVIEW;

ANIMALIA;

ANIMALS; CELL DEATH; CYTOKINES; ENDOPLASMIC RETICULUM STRESS; HUMANS; IMMUNE SYSTEM; MOLECULAR CHAPERONES; NEOPLASMS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84890034987     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2013.48     Document Type: Review

References (129)

1. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012; 12: 860-875.
2. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2012; 31: 51-72.
3. Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. Nat Rev Immunol 2009; 9: 353-363.
4. Gregory CD, Pound JD. Cell death in the neighbourhood: Direct microenvironmental effects of apoptosis in normal and neoplastic tissues. J Pathol 2010; 223: 177-194.
5. Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV, Agostinis P. Immunogenic cell death, DAMPs and anticancer therapeutics: An emerging amalgamation. Biochim Biophys Acta 2010; 1805: 53-71.
6. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13: 54-61.
7. Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J 2012; 31: 1062-1079.
8. Garg AD, Kaczmarek A, Krysko O, Vandenabeele P, Krysko DV, Agostinis P. ER stressinduced inflammation: Does it aid or impede disease progression? Trends Mol Med 2012; 18: 589-598.
9. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N et al. Caspasedependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202: 1691-1701.
10. Verfaillie T, Garg AD, Agostinis P. Targeting ER stress induced apoptosis and inflammation in cancer. Cancer Lett 2010; 332: 249-264.
11. Garg AD, Krysko DV, Vandenabeele P, Agostinis P. The emergence of phox-ER stress induced immunogenic apoptosis. OncoImmunology 2012; 1: 786-788.
12. Dudek AM, Garg AD, Krysko DV, De Ruysscher D, Agostinis P. Inducers of immunogenic cancer cell death. Cytokine Growth Factor Rev 2013; S1359-6101: 00006-3.
13. Garg AD, Krysko DV, Vandenabeele P, Agostinis P. DAMPs and PDT-mediated photooxidative stress: Exploring the unknown. Photochem Photobiol Sci 2011; 10: 670-680.
14. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991-1045.
15. Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC et al. Mechanisms of pre-Apoptotic calreticulin exposure in immunogenic cell death. EMBO J 2009; 28: 578-590.
16. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-1059.
17. Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 2008; 15: 3-12.
18. Callahan MK, Chaillot D, Jacquin C, Clark PR, Menoret A. Differential acquisition of antigenic peptides by Hsp70 and Hsc70 under oxidative conditions. J Biol Chem 2002; 277: 33604-33609.
19. Chiang CL, Ledermann JA, Aitkens E, Benjamin E, Katz DR, Chain BM. Oxidation of ovarian epithelial cancer cells by hypochlorous acid enhances immunogenicity and stimulates T cells that recognize autologous primary tumor. Clin Cancer Res 2008; 14: 4898-4907.
20. Chang MK, Binder CJ, Miller YI, Subbanagounder G, Silverman GJ, Berliner JA et al. Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory. J Exp Med 2004; 200: 1359-1370.
21. Miller YI, Choi SH, Wiesner P, Fang L, Harkewicz R, Hartvigsen K et al. Oxidation-specific epitopes are danger-Associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res 2011; 108: 235-248.
22. Garg AD, Krysko DV, Vandenabeele P, Agostinis P. Hypericin-based photodynamic therapy induces surface exposure of damage-Associated molecular patterns like HSP70 and calreticulin. Cancer Immunol Immunother 2012; 61: 215-221.
23. Yang Y, Li XJ, Chen Z, Zhu XX, Wang J, Zhang LB et al. Wogonin induced calreticulin/ annexin A1 exposure dictates the immunogenicity of cancer cells in a PERK/AKT dependent manner. PLoS One 2012; 7: E50811.
24. Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Shen S et al. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med 2012; 4: 143ra99.
25. Verfaillie T, Rubio N, Garg AD, Bultynck G, Rizzuto R, Decuypere JP et al. PERK is required at the ER-mitochondrial contact sites to convey apoptosis after ROS-based ER stress. Cell Death Differ 2012; 19: 1880-1891.
26. Miyamoto S, Inoue H, Nakamura T, Yamada M, Sakamoto C, Urata Y et al. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. Cancer Res 2012; 72: 2609-2621.
27. He B. Viruses, endoplasmic reticulum stress, and interferon responses. Cell Death Differ 2006; 13: 393-403.
28. Tong AW, Senzer N, Cerullo V, Templeton NS, Hemminki A, Nemunaitis J. Oncolytic viruses for induction of anti-Tumor immunity. Curr Pharm Biotechnol 2012; 13: 1750-1760.
29. Zitvogel L, Kroemer G, Delahaye N, Ma Y, Kepp O. Compounds and uses thereof to induce an immunogenic cancer cell death in a subject In: Office USPT (ed). http:// www.freepatentsonline.com/y2013/0052160.html. US Patent Trademark Office: USA. URL: Http://www.freepatentsonline.com/y2013/0052160.html. Institut Gustave Roussy: Villejuif, France, 2013.
30. Garg AD, Nowis D, Golab J, Agostinis P. Photodynamic therapy: Illuminating the road from cell death towards anti-Tumour immunity. Apoptosis 2010; 15: 1050-1071.
31. Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 2011; 208: 1989-2003.
32. Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med 2011; 208: 2005-2016.
33. Lorenzi S, Mattei F, Sistigu A, Bracci L, Spadaro F, Sanchez M et al. Type I IFNs control antigen retention and survival of CD8alpha(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming. J Immunol 2011; 186: 5142-5150.
34. Fuertes MB, Woo SR, Burnett B, Fu YX, Gajewski TF. Type I interferon response and innate immune sensing of cancer. Trends Immunol 2013; 34: 67-73.
35. Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S, Dhodapkar MV. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: Therapeutic implications. Blood 2007; 109: 4839-4845.
36. Gopal U, Bohonowych JE, Lema-Tome C, Liu A, Garrett-Mayer E, Wang B et al. A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion. PLoS One 2011; 6: E17649.
37. Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-Activation of LRP on the phagocyte. Cell 2005; 123: 321-334.
38. Pawaria S, Binder RJ. CD91-dependent programming of T-helper cell responses following heat shock protein immunization. Nat Commun 2011; 2: 521.
39. Zappasodi R, Pupa SM, Ghedini GC, Bongarzone I, Magni M, Cabras AD et al. Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. Cancer Res 2010; 70: 9062-9072.
40. Song S, Zhou F, Chen WR, Xing D. PDT-induced HSP70 externalization up-regulates NO production via TLR2 signal pathway in macrophages. FEBS Lett 2012; 587: 128-135.
41. Fucikova J, Kralikova P, Fialova A, Brtnicky T, Rob L, Bartunkova J et al. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res 2011; 71: 4821-4833.
42. Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 2009; 461: 282-286.
43. Kariko K, Ni H, Capodici J, Lamphier M, Weissman D. mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem 2004; 279: 12542-12550.
44. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15: 1170-1178.
45. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P et al. Autophagydependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334: 1573-1577.
46. Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H et al. Tumorinfiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol 2012; 13: 832-842.
47. Behrens MD, Wagner WM, Krco CJ, Erskine CL, Kalli KR, Krempski J et al. The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity. Blood 2008; 111: 1472-1479.
48. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-Associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237-241.
49. Hu DE, Moore AM, Thomsen LL, Brindle KM. Uric acid promotes tumor immune rejection. Cancer Res 2004; 64: 5059-5062.
50. Krysko DV, Agostinis P, Krysko O, Garg AD, Bachert C, Lambrecht BN et al. Emerging role of damage-Associated molecular patterns derived from mitochondria in inflammation. Trends Immunol 2011; 32: 157-164.
51. Jube S, Rivera Z, Bianchi ME, Powers A, Wang E, Pagano IS et al. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res 2012; 72: 3290-3301.
52. Palumbo R, Sampaolesi M, De Marchis F, Tonlorenzi R, Colombetti S, Mondino A et al. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol 2004; 164: 441-449.
53. Yang D, Postnikov YV, Li Y, Tewary P, de la Rosa G, Wei F et al. High-mobility group nucleosome-binding protein 1 acts as an alarmin and is critical for lipopolysaccharideinduced immune responses. J Exp Med 2012; 209: 157-171.
54. Cohen I, Rider P, Carmi Y, Braiman A, Dotan S, White MR et al. Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. Proc Natl Acad Sci USA 2010; 107: 2574-2579.
55. Luthi AU, Cullen SP, McNeela EA, Duriez PJ, Afonina IS, Sheridan C et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 2009; 31: 84-98.
56. Panaretakis T, Joza N, Modjtahedi N, Tesniere A, Vitale I, Durchschlag M et al. The co-Translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ 2008; 15: 1499-1509.
57. Garg AD, Bose M, Ahmed MI, Bonass WA, Wood SR. In vitro studies on erythrosinebased photodynamic therapy of malignant and pre-malignant oral epithelial cells. PLoS One 2012; 7: E34475.
58. Chang CL, Hsu YT, Wu CC, Yang YC, Wang C, Wu TC et al. Immune mechanism of the antitumor effects generated by bortezomib. J Immunol 2012; 189: 3209-3220.
59. Baltzis D, Qu LK, Papadopoulou S, Blais JD, Bell JC, Sonenberg N et al. Resistance to vesicular stomatitis virus infection requires a functional cross talk between the eukaryotic translation initiation factor 2alpha kinases PERK and PKR. J Virol 2004; 78: 12747-12761.
60. Pavio N, Romano PR, Graczyk TM, Feinstone SM, Taylor DR. Protein synthesis and endoplasmic reticulum stress can be modulated by the hepatitis C virus envelope protein E2 through the eukaryotic initiation factor 2alpha kinase PERK. J Virol 2003; 77: 3578-3585.
61. Krishnamoorthy J, Mounir Z, Raven JF, Koromilas AE. The eIF2alpha kinases inhibit vesicular stomatitis virus replication independently of eIF2alpha phosphorylation. Cell Cycle 2008; 7: 2346-2351.
62. Franz S, Herrmann K, Furnrohr BG, Sheriff A, Frey B, Gaipl US et al. After shrinkage apoptotic cells expose internal membrane-derived epitopes on their plasma membranes. Cell Death Differ 2007; 14: 733-742.
63. Chekeni FB, Elliott MR, Sandilos JK, Walk SF, Kinchen JM, Lazarowski ER et al. Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis. Nature 2010; 467: 863-867.
64. Garg AD, Dudek AM, Ferreira GB, Verfaillie T, Vandenabeele P, Krysko DV et al. ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death. Autophagy 2013 (accepted).
65. Mestas J, Hughes CC. Of mice and not men: Differences between mouse and human immunology. J Immunol 2004; 172: 2731-2738.
66. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 2013; 110: 3507-3512.
67. Ma Y, Aymeric L, Locher C, Mattarollo SR, Delahaye NF, Pereira P et al. Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med 2011; 208: 491-503.
68. Romagnani S. Human TH1 and TH2 subsets: Doubt no more. Immunol Today 1991; 12: 256-257.
69. Gor DO, Rose NR, Greenspan NS. TH1-TH2: A procrustean paradigm. Nat Immunol 2003; 4: 503-505.
70. Del Prete G, De Carli M, Almerigogna F, Giudizi MG, Biagiotti R, Romagnani S. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 1993; 150: 353-360.
71. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264.
72. Matarese G, La Cava A, Horvath TL. In vivo veritas, in vitro artificia. Trends Mol Med 2012; 18: 439-442.
73. Munn DH. Blocking IDO activity to enhance anti-Tumor immunity. Front Biosci (Elite Ed) 2012; 4: 734-745.
74. Sucher R, Kurz K, Weiss G, Margreiter R, Fuchs D, Brandacher G. IDO-mediated tryptophan degradation in the pathogenesis of malignant tumor disease. Int J Tryptophan Res 2010; 3: 113-120.
75. Huang W, Ramsey KM, Marcheva B, Bass J. Circadian rhythms, sleep, and metabolism. J Clin Invest 2011; 121: 2133-2141.
76. Zen M, Ghirardello A, Iaccarino L, Tonon M, Campana C, Arienti S et al. Hormones, immune response, and pregnancy in healthy women and SLE patients. Swiss Med Wkly 2010; 140: 187-201.
77. Berthois Y, Katzenellenbogen JA, Katzenellenbogen BS. Phenol red in tissue culture media is a weak estrogen: Implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci USA 1986; 83: 2496-2500.
78. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000; 25: 187-191.
79. Verma D, Lerm M, Blomgran Julinder R, Eriksson P, Soderkvist P, Sarndahl E. Gene polymorphisms in the NALP3 inflammasome are associated with interleukin-1 production and severe inflammation: Relation to common inflammatory diseases? Arthritis Rheum 2008; 58: 888-894.
80. Verma D, Sarndahl E, Andersson H, Eriksson P, Fredrikson M, Jonsson JI et al. The Q705K polymorphism in NLRP3 is a gain-of-function alteration leading to excessive interleukin-1beta and IL-18 production. PLoS One 2012; 7: E34977.
81. Netea MG, Wijmenga C, O'Neill LA. Genetic variation in Toll-like receptors and disease susceptibility. Nat Immunol 2012; 13: 535-542.
82. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15: 1170-1178.
83. Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010; 29: 482-491.
84. Schiraldi M, Raucci A, Munoz LM, Livoti E, Celona B, Venereau E et al. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med 2012; 209: 551-563.
85. Unlu S, Tang S, Wang E, Martinez I, Tang D, Bianchi ME et al. Damage associated molecular pattern molecule-induced microRNAs (DAMPmiRs) in human peripheral blood mononuclear cells. PLoS One 2012; 7: E38899.
86. Junger WG. Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol 2011; 11: 201-212.
87. Michaud M, Sukkurwala AQ, Martins I, Shen S, Zitvogel L, Kroemer G. Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39. OncoImmunology 2012; 1: 393-395.
88. Lu B, Nakamura T, Inouye K, Li J, Tang Y, Lundback P et al. Novel role of PKR in inflammasome activation and HMGB1 release. Nature 2012; 488: 670-674.
89. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000; 192: 565-570.
90. He Y, Zha J, Wang Y, Liu W, Yang X, Yu P. Tissue damage-Associated ''danger signals'' influence T-cell responses that promote the progression of preneoplasia to cancer. Cancer Res 2013; 73: 629-639.
91. Bruchard M, Mignot G, Derangere V, Chalmin F, Chevriaux A, Vegran F et al. Chemotherapy-Triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 2013; 19: 57-64.
92. Thery C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol 2006; Chapter 3(Unit 3): 22.
93. Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W, Geuze HJ. Exosome: From internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 2000; 113(Pt 19): 3365-3374.
94. Thery C, Zitvogel L, Amigorena S. Exosomes: Composition, biogenesis and function. Nat Rev Immunol 2002; 2: 569-579.
95. Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008; 10: 1470-1476.
96. Nazarenko I, Rana S, Baumann A, McAlear J, Hellwig A, Trendelenburg M et al. Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation. Cancer Res 2010; 70: 1668-1678.
97. Marleau AM, Chen CS, Joyce JA, Tullis RH. Exosome removal as a therapeutic adjuvant in cancer. J Transl Med 2012; 10: 134.
98. Ichim TE, Zhong ZH, Kaushal S, Zheng XF, Ren XB, Hao XS et al. Exosomes as a tumor immune escape mechanism: Possible therapeutic implications. J Transl Med 2008; 6: 37.
99. Andreola G, Rivoltini L, Castelli C, Huber V, Perego P, Deho P et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 2002; 195: 1303-1316.
100. Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, Tabi Z. Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol 2008; 180: 7249-7258.
101. Xiang XY, Poliakov A, Liu C, Liu YL, Deng ZB, Wang JH et al. Induction of myeloidderived suppressor cells by tumor exosomes. Int J Cancer 2009; 124: 2621-2633.
102. Clayton A, Al-Taei S, Webber J, Mason MD, Tabi Z. Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. J Immunol 2011; 187: 676-683.
103. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204: 1257-1265.
104. Peinado H, Lavotshkin S, Lyden D. The secreted factors responsible for pre-metastatic niche formation: Old sayings and new thoughts. Semin Cancer Biol 2011; 21: 139-146.
105. Alderton GK. Metastasis. Exosomes drive premetastatic niche formation. Nat Rev Cancer 2012; 12: 447.
106. Elsner L, Muppala V, Gehrmann M, Lozano J, Malzahn D, Bickeboller H et al. The heat shock protein HSP70 promotes mouse NK cell activity against tumors that express inducible NKG2D ligands. J Immunol 2007; 179: 5523-5533.
107. Smalheiser NR. Exosomal transfer of proteins and RNAs at synapses in the nervous system. Biol Direct 2007; 2: 35.
108. Eustace BK, Jay DG. Extracellular roles for the molecular chaperone, hsp90. Cell Cycle 2004; 3: 1098-1100.
109. Radons J, Multhoff G. Immunostimulatory functions of membrane-bound and exported heat shock protein 70. Exerc Immunol Rev 2005; 11: 17-33.
110. Wolfers J, Lozier A, Raposo G, Regnault A, Thery C, Masurier C et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 2001; 7: 297-303.
111. Zhang HG, Liu C, Su K, Yu S, Zhang L, Zhang S et al. A membrane form of TNF-Alpha presented by exosomes delays T cell activation-induced cell death. J Immunol 2006; 176: 7385-7393.
112. Lazear HM, Lancaster A, Wilkins C, Suthar MS, Huang A, Vick SC et al. IRF-3, IRF-5, and IRF-7 coordinately regulate the type I IFN response in myeloid dendritic cells downstream of MAVS signaling. PLoS Pathog 2013; 9: E1003118.
113. Barnes BJ, Field AE, Pitha-Rowe PM. Virus-induced heterodimer formation between IRF-5 and IRF-7 modulates assembly of the IFNA enhanceosome in vivo and transcriptional activity of IFNA genes. J Biol Chem 2003; 278: 16630-16641.
114. Pien GC, Satoskar AR, Takeda K, Akira S, Biron CA. Cutting edge: Selective IL-18 requirements for induction of compartmental IFN-gamma responses during viral infection. J Immunol 2000; 165: 4787-4791.
115. Szretter KJ, Gangappa S, Lu X, Smith C, Shieh WJ, Zaki SR et al. Role of host cytokine responses in the pathogenesis of avian H5N1 influenza viruses in mice. J Virol 2007; 81: 2736-2744.
116. Garrido G, Rabasa A, Sanchez B, Lopez MV, Blanco R, Lopez A et al. Induction of immunogenic apoptosis by blockade of epidermal growth factor receptor activation with a specific antibody. J Immunol 2011; 187: 4954-4966.
117. Cirone M, Di Renzo L, Lotti LV, Conte V, Trivedi P, Santarelli R et al. Primary effusion lymphoma cell death induced by bortezomib and AG 490 activates dendritic cells through CD91. PLoS One 2012; 7: E31732.
118. Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili P, Spadaro F et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res 2011; 71: 768-778.
119. Weibel S, Raab V, Yu YA, Worschech A, Wang E, Marincola FM et al. Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection. BMC Cancer 2011; 11: 68.
120. Mahoney DJ, Lefebvre C, Allan K, Brun J, Sanaei CA, Baird S et al. Virus-Tumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virus-Triggered caspase-2 cell death. Cancer Cell 2011; 20: 443-456.
121. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret al.ly: Immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11: 215-233.
122. Schroder K, Tschopp J. The inflammasomes. Cell 2010; 140: 821-832.
123. Koenen HJ, Smeets RL, Vink PM, van Rijssen E, Boots AM, Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008; 112: 2340-2352.
124. Beutler B. Tlr4: Central component of the sole mammalian LPS sensor. Curr Opin Immunol 2000; 12: 20-26.
125. Donnelly-Roberts DL, Namovic MT, Han P, Jarvis MF. Mammalian P2-7 receptor pharmacology: Comparison of recombinant mouse, rat and human P2-7 receptors. Br J Pharmacol 2009; 157: 1203-1214.
126. Liu Z, Miner JJ, Yago T, Yao L, Lupu F, Xia L et al. Differential regulation of human and murine P-selectin expression and function in vivo. J Exp Med 2010; 207: 2975-2987.
127. Lima LG, Chammas R, Monteiro RQ, Moreira ME, Barcinski MA. Tumor-derived microvesicles modulate the establishment of metastatic melanoma in a phosphatidylserine-dependent manner. Cancer Lett 2009; 283: 168-175.
128. Andre F, Schartz NE, Movassagh M, Flament C, Pautier P, Morice P et al. Malignant effusions and immunogenic tumour-derived exosomes. Lancet 2002; 360: 295-305.
129. Connell PP, Weichselbaum RR. A downside to apoptosis in cancer therapy? Nat Med 2011; 17: 780-782.